Protocolo de prevención primaria y secundaria de la cardiopatía isquémica

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Medicine - Programa de Formación Médica Continuada Acreditado

• Publication date

  2025-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.med.2025.10.008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• 2023 ESC Guidelines for the management of acute coronary syndromes.

  2023cited by this paper
• 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

  2023cited by this paper
• Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica

  2022cited by this paper
• Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.

  2021cited by this paper
• SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.

  2021cited by this paper
• Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

  2021cited by this paper
• SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.

  2021cited by this paper
• Factors Associated with Return to Work Following Myocardial Infarction: A Systematic Review of Observational Studies.

  2020cited by this paper
• Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology.

  2020cited by this paper
• Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.

  2020cited by this paper
• SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

  2020cited by this paper
• Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

  2019cited by this paper
• Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

  2019cited by this paper
• Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

  2019cited by this paper
• Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

  2019cited by this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cited by this paper
• Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

  2019cited by this paper
• Evaluating the effectiveness of the NHS Health Check programme in South England: a quasi-randomised controlled trial

  2019cited by this paper
• Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS).

  2019cited by this paper
• Ambient Particulate Air Pollution and Daily Mortality in 652 Cities.

  2019cited by this paper
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

  2019cited by this paper
• Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial.

  2019cited by this paper
• Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019

  2019cited by this paper
• Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis

  2018cited by this paper
• Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

  2018cited by this paper
• Environmental Noise and the Cardiovascular System.

  2018cited by this paper
• Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

  2018cited by this paper
• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

  2017cited by this paper
• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

  2017cited by this paper
• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

  2017cited by this paper
• Cognitive Function in a Randomized Trial of Evolocumab

  2017cited by this paper
• Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

  2017cited by this paper
• Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.

  2016cited by this paper
• Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.

  2016cited by this paper
• Climate and environmental triggers of acute myocardial infarction

  2016cited by this paper
• Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

  2015cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

  2014cited by this paper
• Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

  2014cited by this paper
• Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.

  2014cited by this paper
• Effectiveness of general practice-based health checks: a systematic review and meta-analysis.

  2014cited by this paper
• Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial

  2014cited by this paper
• Primary prevention of cardiovascular disease with a Mediterranean diet.

  2013cited by this paper
• General health checks in adults for reducing morbidity and mortality from disease.

  2012cited by this paper
• Estimating treatment effects for individual patients based on the results of randomised clinical trials

  2011cited by this paper
• Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.

  2008cited by this paper
• Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

  2003cited by this paper
• Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction

  2003cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Multiple risk factor interventions for primary prevention of coronary heart disease.

  2000cited by this paper
• An evidence based approach to individualising treatment

  1995cited by this paper
• A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

  1995cited by this paper
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

  1993cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper

• No citing papers are available for this paper.